No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
ICT-107 is a cancer vaccine developed by ImmunoCellular Therapeutics, Ltd. It is a dendritic cell-based vaccine designed to target multiple tumor-associated antigens, including telomerase, survivin, and MUC-1. The vaccine is intended to stimulate the patient's immune system to recognize and attack cancer cells. It is currently in Phase II clinical trials for the treatment of glioblastoma multiforme, a type of brain cancer.
The ICT-107 market is a rapidly growing segment of the cancer vaccine industry. It is driven by the increasing prevalence of cancer and the need for more effective treatments. The market is expected to benefit from advances in immunotherapy and the development of personalized cancer vaccines.
Companies in the ICT-107 market include ImmunoCellular Therapeutics, Ltd., Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, and Bristol-Myers Squibb Company. Show Less Read more
